Please visit our MS learning channel on Youtube, which provides hundreds of topics from our education programs, that were video-recorded and archived here: www.youtube.com/msviewsandnews -- Be empowered with MS news by registering with us: www.register.msviewsandnews.org

joomla ecommerce template -- Scroll left side of this blog for needed resources. Also, use our 'search by topic' tool, to find specific information.

Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.

============================================================

Wednesday, May 11, 2016

Opexa’s CEO Gives Update on T-Cell Therapy for NMO, MS and other autoimmune disorders

                                                                  

Click here to receive MS news via e-mail        
 



Opexa Therapeutics, Inc., announced that its president and chief executive officer, Neil K. Warma, recently gave a presentation on immunotherapy and its potential for treating autoimmune disorders, including multiple sclerosis, at the recent Cellular Horizons: The Third International Conference on the Progress of Regenerative Medicine and its Cultural Impact held at the Vatican.
Neil K. Warma
Neil K. Warma
Mr. Warma’s presentation was titled, “Can T-cells be Used to Treat Neuromyelitis Optica (NMO) and Other Autoimmune Disorders?
Opexa’s leading therapeutic candidate, Tcelna, developed using the company’s proprietary T-cell technology, is a personalized T-cell immunotherapy now in a Phase 2b clinical development program (Abili-T) for the treatment of secondary progressive MS. The therapy consists of myelin-reactive T-cells that are recovered from patients ‘peripheral blood, expanded, and subsequently reintroduced in an attenuated form via subcutaneous injection. The process is designed to trigger a powerful immune response against subsets of autoreactive T-cells that attack myelin.
Read more






~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
MS Views and News
Provides educational information, resources and services for those affected by MS
We Believe YOU (the MS Patients and Caregivers) should Be Empowered with Multiple Sclerosis information
.===================================



No comments: